



Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

Figure S1. Comparison of Progression-Free Survival (PFS) and Overall Survival (OS) Between Study Patients Who Did and Did Not Experience IRAEs by Gender.

A. PFS in Women




B. OS in Women




Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

C. PFS in Men




D. OS in Men




Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

Figure S2. Comparison of Progression-Free Survival (PFS) and Overall Survival (OS) Between Study Patients Who Did and Did Not Experience IRAEs by Enrolling Institution

A. PFS at Site 1 (VICC)




B. OS at Site 1 (VICC)




Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

C. PFS at Site 2 (WCE)




D. OS at Site 2 (WCE)




Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

E. PFS at Site 3 (SCI)




F. OS at Site 3 (SCI)




Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA
Approved Indications for Immunotherapy
Satya Das et al.

Figure S3. Comparison of Progression-Free Survival (PFS) and Overall Survival (OS) Between Study Patients by Specific IRAE Site (Dermatologic vs Non-Dermatologic)

A. PFS




B. OS



Supplemental Figures for:
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Gastrointestinal Cancer Patients with FDA Approved Indications for Immunotherapy
Satya Das et al.

Figure S4. Comparison of Progression-Free Survival (PFS) and Overall Survival (OS) Between Study Patients by Number of IRAEs

A. PFS



B. OS

